Curis Reports Third Quarter 2016 Financial Results
November 03, 2016 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Release Third Quarter 2016 Financial Results and Hold Conference Call on November 3, 2016
October 27, 2016 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 11, 2016 07:05 ET
|
Curis, Inc
LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist
October 11, 2016 07:00 ET
|
Curis, Inc
CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration ...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 16, 2016 10:26 ET
|
Curis, Inc
LEXINGTON, Mass., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Aurigene to Invest in Curis at Premium Through Waiver of Certain Milestone Payments Under Collaboration Agreement
September 07, 2016 06:55 ET
|
Curis, Inc
LEXINGTON, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Present at Baird’s 2016 Global Healthcare Conference
August 31, 2016 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis Reports Second Quarter 2016 Financial Results
August 04, 2016 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Release Second Quarter 2016 Financial Results and Hold Conference Call on August 4, 2016
July 28, 2016 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule Drug Candidate to Target and Inhibit Immune Checkpoints
June 21, 2016 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...